Latest From FibroGen Inc.
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.
Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.
Astellas becomes first to market in Japan in new class of oral anemia drugs, beating multiple rivals in a sector set to see strong growth but also fierce competition.
Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Hepatic (Liver)
- Musculoskeletal & Connective Tissue Disorders
- Renal System
- North America
- Parent & Subsidiaries
- FibroGen Inc.
- Senior Management
Enrique Conterno, CEO
Pat Cotroneo, VP, Fin. & CFO
David M Dimmick, MD, VP, Quality
R. Wayne Frost, VP, RA
Elias Kouchakji, MD, VP, Clinical Dev and Drug Safety
AI Lin, MD, PhD, VP, Drug Dev.
Peony K Yu, CMO
- Contact Info
Phone: (415) 978-1200
409 Illinois St.
San Francisco, CA 94158
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.